术中应用5-FU缓释剂治疗晚期卵巢癌的近期疗效观察  

Recent Curative Effect Observation of Sustained-release 5-Fluorouracil Used during Operation in Patients with Advanced Ovarian Elithelial Carcinoma

作　　者：江源[1] 韩克[1] 周怀君[1] 凌静娴[1] 周白[1] 李荣[1] 翁乔[1] 

机构地区：[1]南京大学医学院附属鼓楼医院妇产科,210008

出　　处：《医学研究杂志》2013年第9期113-117,共5页Journal of Medical Research

摘　　要：目的 探讨手术中使用氟尿嘧啶缓释剂治疗晚期卵巢癌的近期疗效和不良反应.方法 对南京市鼓楼医院2006年9月～2011年10月间病理诊断的62例晚期卵巢癌患者进行回顾分析,分为两组,研究组术中植入5-FU缓释剂＋术后TP方案化疗和对照组仅行术后TP化疗.结果 对两组患者术前的CA125水平比较,差异无统计学意义（P＞0.05）.第1次化疗后,研究组比对照组的CA125下降明显（P＜0.05）,但第2次、第3次和第4次化疗后两组的CA125水平比较,差异无统计学意义（P＞0.05）.初治卵巢癌患者研究组与对照组比较,第1次化疗后,研究组比对照组CA125下降明显（P＜0.05）,复发卵巢癌患者经第1次或第2次化疗后,研究组比对照组的CA125下降明显（P＜0.05）.研究组治疗后腹腔积液缓解率为68％,盆腔肿块缩小为47％,淋巴结转移者有效率为30％.两组在白细胞减少、贫血,血小板减少、胃肠道反应,肝、肾功能损害及脱发等方面比较,差异均无统计学意义（P＞0.05）.结论 在经过理想的卵巢肿瘤细胞减灭术的晚期卵巢癌患者中,术中运用5-FU缓释剂腹腔化疗有效可行,特别是对于复发性的卵巢癌患者有较好的近期疗效,且不增加患者的不良反应,临床上可以接受.Objective To evaluate the efficacy and side effects of sustained-release 5-Fluorouracil used during operation in the treatment of advanced ovarian elithelial carcinoma.Methods Retrospective analysis was utilized to analyze 62 advanced ovarian cancer patients diagnosed definitely by pathology in the Nanjing Drum Tower Hospital from September 2006 to October 2011.The patients were divided into two groups.The group of sustained-release 5-fluorouracil used during operation combined with TP chemotherapy after operation was as research group,and the group of TP chemotherapy only after operation was as control group.Results As for the preoperative CA125 levels of the two groups,the difference was not statistically significant（P 〉 0.05）.After the first cycle chemotherapy,CA125 levels in reseach group were lower than those in control group（P 〈 0.05）,but there was no significant difference between two groups after second,third or fourth cycle chemotherapy（P 〉 0.05）.For first treatment ovarian cancer patients,CA125 levels in research group were lower than those in control group after first cycle（P 〈 0.05）.For the recurrent ovarian cance patients,CA125 levels in research group were lower than those in control group after first and second cycle（P 〈 0.05）.Ascites effective rate was 68%,Pelvic mass effective rate was 47% Lymph node metastasis effective rate was 30% in the research group,but there was no significant differences between two groups in the toxicities of hypoleukemia,anemia,thrombocytopenia digestive disturbance,liver function damage,renal function damage,phalacrosis.Conclusion Intraoperative use of sustained-release 5-fluorouracil intraperitoneal chemotherapy is effective and feasible for the advanced ovarian cancer after optimally cytoreductive surgery in particular to recurrent ovarian cancer,and does not increase toxicity in patients,so it can be clinically acceptable.

关 键 词：卵巢肿瘤 药物疗法 缓释化疗 氟尿嘧啶 

分 类 号：R735.37[医药卫生—肿瘤]